Developer docs
API playgroundTry for free, no card

Search company profiles

NodeAI Diagnostics

Full company profile

uuid00eriid

Namestring
NodeAI Diagnostics
Legal namestring
NodeAI Diagnostics Corp.
Websiteurl
nodeai.ca
Company typeenum
Private
Founded yearint
2023
Descriptiontext

NodeAI Diagnostics Corp. is a Hamilton, Ontario-based medical device software company founded in late 2023 that develops AI-driven tools to improve lung cancer staging by enhancing ultrasound analysis during EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration) procedures. The company's platform addresses the clinical problem that approximately 40% of EBUS-TBNA procedures yield inconclusive or inaccurate staging results due to operator variability and the technical complexity of the procedure, leading to repeat biopsies and treatment delays. NodeAI is targeting healthcare institutions with bronchoscopy suites, thoracic surgeons and interventional pulmonologists, medical learners, and OEM partners who manufacture EBUS towers and processors.

The platform is built on nearly a decade of peer-reviewed research by co-founder and CMO Dr. Waël Hanna and is powered by a proprietary dataset of 3.2M+ ultrasound images and videos paired to pathology, described as one of the largest EBUS datasets in the world. The product suite comprises NodeAI OS (a platform foundation handling video ingestion, image storage, secure model serving, audit logging, and EMR integration, running on NVIDIA-powered edge hardware for bedside inference), NodeAI Guide (real-time lymph node detection and segmentation overlaid on live EBUS ultrasound), NodeAI Predict (per-node calibrated malignancy probability scoring), and NodeAI Analytics (cross-site benchmarking, training, credentialing, and procedure-volume forecasting). Validated performance on a 521-node held-out test set includes 96.91% specificity and an AUC of 0.701 for predicting malignancy from B-mode ultrasound images.

NodeAI is pre-commercial, operating as a research and evaluation platform with products undergoing multi-centre clinical trials (6 active sites with 9 more in activation across North America; ClinicalTrials.gov NCT06540196) and pursuing FDA 510(k) clearance. The planned revenue model is Software as a Medical Device (SaMD) delivered via subscription or licensing to healthcare institutions, with the go-to-motion combining direct enterprise field sales to hospitals and OEM partnerships. To date, the company has been funded exclusively through non-dilutive grants totalling approximately C$750K from FACIT, INOVAIT, and the Ontario Centre of Innovation, and has assembled board advisors including Prof. Kazuhiro Yasufuku (co-inventor of EBUS-TBNA) and Prof. Moishe Liberman.

Short descriptiontext

NodeAI Diagnostics is a Hamilton, Ontario-based medical device software company founded in 2023 that develops AI-driven real-time decision support for EBUS-TBNA lung cancer staging procedures, targeting hospitals, thoracic surgeons, and OEM partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHamilton, Canada
HQ citystring
Hamilton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lung cancer diagnostics, AI medical imaging, EBUS guidance software, clinical decision support, cancer staging AI
Industry2 codes
PRIMARYHLACAPAL
Edge-Based Clinical Decision Support & Alerts (On-Device/On-Prem Analytics)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Computer Systems Design and Related Services54151
SIC code3 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Decision Support Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Software as a Medical Device (SaMD)
TypeSubscription Recurring
Description

NodeAI is developing its platform as Software as a Medical Device. Currently operating as a research and evaluation platform. In future clinical deployments, the company will likely pursue subscription or licensing arrangements with healthcare institutions. The company states it may qualify as SaMD and is pursuing regulatory clearance.

nodeai.ca
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Others, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

NodeAI develops an AI-powered software platform (Software as a Medical Device) that provides near-real-time decision support during EBUS-TBNA procedures for lung cancer staging. The platform delivers real-time lymph node detection and segmentation overlaid on live ultrasound, per-node malignancy probability scores, and cross-site benchmarking and reporting. It runs on an NVIDIA-powered edge device at the bedside, requiring no cloud dependency, and is designed to integrate with standard EBUS towers and processors without disrupting clinical workflow.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 96.91% specificity and AUC of 0.701 for predicting malignancy from B-mode EBUS ultrasound images
+3 more records
Product overview1 text field

NodeAI is a workflow-integrated AI platform for endoscopy-enabled care, consisting of one platform foundation (NodeAI OS) and three intelligent modules (NodeAI Guide, NodeAI Predict, and NodeAI Analytics). NodeAI OS serves as the platform layer handling video ingestion, image storage, secure model serving, audit logging, and EMR integration, running on an NVIDIA-powered edge device at the bedside. NodeAI Guide provides real-time lymph node detection and segmentation during EBUS procedures. NodeAI Predict delivers AI-powered per-node malignancy probability scores. NodeAI Analytics provides procedure benchmarking, training, and quality dashboards across connected sites.

Product and service5 records
1NodeAI OS
CategoryMedical Device Software Platform
Description

NodeAI OS is the platform foundation that hosts all NodeAI modules. It handles video ingestion, image storage and reporting, secure model serving, audit logging, and EMR integration, running on an NVIDIA-powered edge device to deliver real-time analysis at the bedside. Engineered to medical device standards, it is intended for thoracic surgeons, interventional pulmonologists, and endoscopists performing EBUS-TBNA procedures in hospitals and bronchoscopy suites.

2NodeAI Guide
CategoryAI Clinical Decision Support Module
Description

NodeAI Guide performs real-time lymph node detection and segmentation overlaid directly on the live EBUS ultrasound image. As operators sweep through the mediastinum, target lymph nodes are detected, outlined, and tracked automatically, reducing operator variability across experience levels. It is intended for endoscopists and thoracic surgeons performing EBUS-TBNA procedures.

3NodeAI Predict
CategoryAI Clinical Decision Support Module
Description

NodeAI Predict is an AI-powered decision support module that returns a calibrated cancer risk score for each lymph node. It analyzes EBUS images and returns a per-node malignancy probability in seconds before the next biopsy decision, built on pathology-confirmed data. It is intended to assist endoscopists in biopsy targeting during EBUS-TBNA procedures.

4NodeAI Analytics
CategoryHealthcare Analytics and Reporting
Description

NodeAI Analytics is a reporting and benchmarking layer that runs across every connected site. It provides procedure benchmarking, clinical training software, quality dashboards, scorecards, operator analytics, automated reports, case logs, credentialing infrastructure, and procedure-volume forecasting for healthcare institutions and clinical training programs.

5Canada Lymph Node Score (CLNS)
CategoryClinical Scoring System / Diagnostic Framework
Description

The Canada Lymph Node Score (CLNS) is a 4-point ultrasonographic scoring system developed to assess malignancy risk in mediastinal lymph nodes during EBUS-TBNA, designed to standardize how endoscopists identify higher-risk targets for biopsy. It underpins NodeAI's clinical framework and is referenced in the platform's malignancy assessment logic.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Prof. Moishe Liberman (Board Advisor)
Strategic tierCoreTypeOthersAnnounced on2025-10-22
Description

Prof. Liberman is internationally recognized thoracic surgeon and educator, Director of Endoscopic Tracheobronchial and Oesophageal Center (C.E.T.O.C.) at CHUM, and Medical Director of CHUM's Multidisciplinary Robotic, Endoscopic, and Minimally Invasive Surgery Program. Joins as Advisor to Board providing guidance on medical and clinical research matters.

nodeai.ca
2Prof. Kazuhiro Yasufuku (Board Advisor)
Strategic tierCoreTypeOthersAnnounced on2025-10-14
Description

Prof. Yasufuku is globally recognized leader in thoracic surgery and pioneering innovator in lung cancer diagnostics. Co-inventor of EBUS-TBNA procedure. Currently Head of Division of Thoracic Surgery and William Coco Chair in Surgical Innovation for Lung Cancer at University Health Network (UHN). Joins as Advisor to Board providing strategic guidance on lung cancer staging, surgical innovation, and minimally invasive diagnostics.

nodeai.ca
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding team originated from McMaster University where Dr. Waël Hanna serves as Division Head of Thoracic Surgery. Company based in Hamilton, Ontario near McMaster Innovation Park. Represents academic-clinical partnership underpinning technology development.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

NodeAI is part of Hamilton's growing life sciences cluster operating out of or near McMaster Innovation Park. Several of the 10 LSIF recipients are based in Hamilton with operations at MIP.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Listed as part of NodeAI's innovation ecosystem supporting the company's development.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Listed as part of NodeAI's innovation ecosystem supporting the company's development and clinical research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NodeAI Diagnostics

Clinical Decision Support Softwarenodeai.ca

NodeAI Diagnostics is a Hamilton, Ontario-based medical device software company founded in 2023 that develops AI-driven real-time decision support for EBUS-TBNA lung cancer staging procedures, targeting hospitals, thoracic surgeons, and OEM partners.

What NodeAI Diagnostics does

NodeAI Diagnostics Corp. is a Hamilton, Ontario-based medical device software company founded in late 2023 that develops AI-driven tools to improve lung cancer staging by enhancing ultrasound analysis during EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration) procedures. The company's platform addresses the clinical problem that approximately 40% of EBUS-TBNA procedures yield inconclusive or inaccurate staging results due to operator variability and the technical complexity of the procedure, leading to repeat biopsies and treatment delays. NodeAI is targeting healthcare institutions with bronchoscopy suites, thoracic surgeons and interventional pulmonologists, medical learners, and OEM partners who manufacture EBUS towers and processors.

The platform is built on nearly a decade of peer-reviewed research by co-founder and CMO Dr. Waël Hanna and is powered by a proprietary dataset of 3.2M+ ultrasound images and videos paired to pathology, described as one of the largest EBUS datasets in the world. The product suite comprises NodeAI OS (a platform foundation handling video ingestion, image storage, secure model serving, audit logging, and EMR integration, running on NVIDIA-powered edge hardware for bedside inference), NodeAI Guide (real-time lymph node detection and segmentation overlaid on live EBUS ultrasound), NodeAI Predict (per-node calibrated malignancy probability scoring), and NodeAI Analytics (cross-site benchmarking, training, credentialing, and procedure-volume forecasting). Validated performance on a 521-node held-out test set includes 96.91% specificity and an AUC of 0.701 for predicting malignancy from B-mode ultrasound images.

NodeAI is pre-commercial, operating as a research and evaluation platform with products undergoing multi-centre clinical trials (6 active sites with 9 more in activation across North America; ClinicalTrials.gov NCT06540196) and pursuing FDA 510(k) clearance. The planned revenue model is Software as a Medical Device (SaMD) delivered via subscription or licensing to healthcare institutions, with the go-to-motion combining direct enterprise field sales to hospitals and OEM partnerships. To date, the company has been funded exclusively through non-dilutive grants totalling approximately C$750K from FACIT, INOVAIT, and the Ontario Centre of Innovation, and has assembled board advisors including Prof. Kazuhiro Yasufuku (co-inventor of EBUS-TBNA) and Prof. Moishe Liberman.

NodeAI Diagnostics firmographics

Firmographics
Name
NodeAI Diagnostics
Legal name
NodeAI Diagnostics Corp.
Website
https://nodeai.ca
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
NodeAI Diagnostics is a Hamilton, Ontario-based medical device software company founded in 2023 that develops AI-driven real-time decision support for EBUS-TBNA lung cancer staging procedures, targeting hospitals, thoracic surgeons, and OEM partners.
Ownership category
akta.pro rank

NodeAI Diagnostics industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAPAL
Edge-Based Clinical Decision Support & Alerts (On-Device/On-Prem Analytics)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Lung cancer diagnostics
  • AI medical imaging
  • EBUS guidance software
  • Clinical decision support
  • Cancer staging AI

Where NodeAI Diagnostics is headquartered

Location

Headquarters

HQ city
Hamilton
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

NodeAI Diagnostics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Others, Operations, Marketing or Sales

Revenue model

  1. Software as a Medical Device (SaMD): NodeAI is developing its platform as Software as a Medical Device. Currently operating as a research and evaluation platform. In future clinical deployments, the company will likely pursue subscription or licensing arrangements with healthcare institutions. The company states it may qualify as SaMD and is pursuing regulatory clearance.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

NodeAI Diagnostics product offering

Product offering

Core offering

NodeAI develops an AI-powered software platform (Software as a Medical Device) that provides near-real-time decision support during EBUS-TBNA procedures for lung cancer staging. The platform delivers real-time lymph node detection and segmentation overlaid on live ultrasound, per-node malignancy probability scores, and cross-site benchmarking and reporting. It runs on an NVIDIA-powered edge device at the bedside, requiring no cloud dependency, and is designed to integrate with standard EBUS towers and processors without disrupting clinical workflow.

Product overview

NodeAI is a workflow-integrated AI platform for endoscopy-enabled care, consisting of one platform foundation (NodeAI OS) and three intelligent modules (NodeAI Guide, NodeAI Predict, and NodeAI Analytics). NodeAI OS serves as the platform layer handling video ingestion, image storage, secure model serving, audit logging, and EMR integration, running on an NVIDIA-powered edge device at the bedside. NodeAI Guide provides real-time lymph node detection and segmentation during EBUS procedures. NodeAI Predict delivers AI-powered per-node malignancy probability scores. NodeAI Analytics provides procedure benchmarking, training, and quality dashboards across connected sites.

Differentiator

Problem solved

Functional benefit

Products and services

  • NodeAI OS NodeAI OS is the platform foundation that hosts all NodeAI modules. It handles video ingestion, image storage and reporting, secure model serving, audit logging, and EMR integration, running on an NVIDIA-powered edge device to deliver real-time analysis at the bedside. Engineered to medical device standards, it is intended for thoracic surgeons, interventional pulmonologists, and endoscopists performing EBUS-TBNA procedures in hospitals and bronchoscopy suites.
  • NodeAI Guide NodeAI Guide performs real-time lymph node detection and segmentation overlaid directly on the live EBUS ultrasound image. As operators sweep through the mediastinum, target lymph nodes are detected, outlined, and tracked automatically, reducing operator variability across experience levels. It is intended for endoscopists and thoracic surgeons performing EBUS-TBNA procedures.
  • NodeAI Predict NodeAI Predict is an AI-powered decision support module that returns a calibrated cancer risk score for each lymph node. It analyzes EBUS images and returns a per-node malignancy probability in seconds before the next biopsy decision, built on pathology-confirmed data. It is intended to assist endoscopists in biopsy targeting during EBUS-TBNA procedures.
  • NodeAI Analytics NodeAI Analytics is a reporting and benchmarking layer that runs across every connected site. It provides procedure benchmarking, clinical training software, quality dashboards, scorecards, operator analytics, automated reports, case logs, credentialing infrastructure, and procedure-volume forecasting for healthcare institutions and clinical training programs.
  • Canada Lymph Node Score (CLNS) The Canada Lymph Node Score (CLNS) is a 4-point ultrasonographic scoring system developed to assess malignancy risk in mediastinal lymph nodes during EBUS-TBNA, designed to standardize how endoscopists identify higher-risk targets for biopsy. It underpins NodeAI's clinical framework and is referenced in the platform's malignancy assessment logic.

Quantifiable outcome

  • 96.91% specificity and AUC of 0.701 for predicting malignancy from B-mode EBUS ultrasound images
  • +3 more outcomes

Companies that use NodeAI Diagnostics

Customer profile

Segments5 records

Ideal customer profiles2 records

NodeAI Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature5 records

NodeAI Diagnostics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • Prof. Moishe Liberman (Board Advisor)coreOthers · 22 October 2025Prof. Liberman is internationally recognized thoracic surgeon and educator, Director of Endoscopic Tracheobronchial and Oesophageal Center (C.E.T.O.C.) at CHUM, and Medical Director of CHUM's Multidisciplinary Robotic, Endoscopic, and Minimally Invasive Surgery Program. Joins as Advisor to Board providing guidance on medical and clinical research matters.
  • Prof. Kazuhiro Yasufuku (Board Advisor)coreOthers · 14 October 2025Prof. Yasufuku is globally recognized leader in thoracic surgery and pioneering innovator in lung cancer diagnostics. Co-inventor of EBUS-TBNA procedure. Currently Head of Division of Thoracic Surgery and William Coco Chair in Surgical Innovation for Lung Cancer at University Health Network (UHN). Joins as Advisor to Board providing strategic guidance on lung cancer staging, surgical innovation, and minimally invasive diagnostics.
  • McMaster UniversitycoreStrategic or Co-development PartnerFounding team originated from McMaster University where Dr. Waël Hanna serves as Division Head of Thoracic Surgery. Company based in Hamilton, Ontario near McMaster Innovation Park. Represents academic-clinical partnership underpinning technology development.
  • McMaster Innovation ParksupportingStrategic or Co-development PartnerNodeAI is part of Hamilton's growing life sciences cluster operating out of or near McMaster Innovation Park. Several of the 10 LSIF recipients are based in Hamilton with operations at MIP.
  • TIAP (Toronto Institute for Advanced Learning)supportingStrategic or Co-development PartnerListed as part of NodeAI's innovation ecosystem supporting the company's development.
  • St. Joseph's ResearchsupportingStrategic or Co-development PartnerListed as part of NodeAI's innovation ecosystem supporting the company's development and clinical research.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

NodeAI Diagnostics competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

NodeAI Diagnostics social profiles

Digital presence

NodeAI Diagnostics compliance and trust

Trust signal

Compliance5 records

NodeAI Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NodeAI Diagnostics leadership team

Management profile

Number of profiles

Profiles9 records

NodeAI Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NodeAI Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NodeAI Diagnostics

What does NodeAI Diagnostics do?

NodeAI develops an AI-powered software platform (Software as a Medical Device) that provides near-real-time decision support during EBUS-TBNA procedures for lung cancer staging. The platform delivers real-time lymph node detection and segmentation overlaid on live ultrasound, per-node malignancy probability scores, and cross-site benchmarking and reporting. It runs on an NVIDIA-powered edge device at the bedside, requiring no cloud dependency, and is designed to integrate with standard EBUS towers and processors without disrupting clinical workflow.

Is NodeAI Diagnostics a public or private company?

NodeAI Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NodeAI Diagnostics founded?

NodeAI Diagnostics was founded in 2023. It employs 1 to 10 people.

Where is NodeAI Diagnostics based?

NodeAI Diagnostics is headquartered in Hamilton, Canada, in the North America region.

How does NodeAI Diagnostics make money?

One revenue line is on record: software as a Medical Device (SaMD).

Does NodeAI Diagnostics have an API?

No public API is recorded for NodeAI Diagnostics.

What industry is NodeAI Diagnostics in?

NodeAI Diagnostics's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAPAL, Edge-Based Clinical Decision Support & Alerts (On-Device/On-Prem Analytics), with a secondary code of HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation). Its NAICS code is 5417 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals